news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

recently, bgi (300676.sz) released its 2024 interim report, achieving operating income of 1.87 billion yuan in the first half of the year and a net profit of 18.1998 million yuan attributable to shareholders of the listed company, and the gross profit margins of many of the company's businesses have increased. the details revealed behind the financial data are even more worthy of careful study. behind this is the dual "concert" of bgi's diversified strategic layout and innovative genes.

the diversified layout of the five major business sectors built by bgi is like five horses running side by side, which greatly enhances the company's market adaptability and risk resistance. in particular, the two major business areas of reproductive health and tumor and chronic disease prevention and control have "shine brightly" in the first half of this year. not only has the business scale continued to expand, but also with excellent market performance, it has added a strong stroke to the company's future development blueprint, showing unlimited growth potential and broad development prospects.

all these achievements are due to bgi's unremitting efforts and huge investment in r&d and innovation. the company attaches great importance to r&d, continuously launches new technologies and new products, and fully embraces the digital strategy, which is expected to further broaden the company's business boundaries and development space, and win the company an advantage in the fierce market competition, injecting continuous vitality into the company's sustainable development.